ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed to improve cytotoxicity against multiple myeloma. Targeting of two tumor-associated an...
Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Nature Research
2024
|